SCHEDULE: RTW Investments Discloses Stake in Tango Therapeutics

RTW Investments, LP and Roderick Wong report beneficial ownership of 9.3% of Tango Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• RTW Investments, LP, an investment adviser, and its Managing Partner, Roderick Wong, have filed a Schedule 13G.
• This filing indicates their beneficial ownership of 13,300,620 shares of Tango Therapeutics, Inc. common stock.
• This ownership stake represents 9.3% of the company's outstanding common stock.
• The shares are held by RTW Funds, for which RTW Investments serves as the investment adviser.
• The filing date for this statement is March 31, 2026, with the report being filed on May 15, 2026.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a standard disclosure of a significant investment position by an institutional investor, not an indicator of company performance.

Positives

• RTW Investments, a significant investment entity, has disclosed a substantial ownership stake, indicating confidence in Tango Therapeutics.
• The ownership is reported as being held in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Risks

• While not explicitly stated as a risk, any significant shift in holdings by major investors like RTW Investments could impact Tango Therapeutics' stock price.
• The filing does not detail the specific RTW Funds holding the shares, which could be a point of interest for further due diligence.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Tango Therapeutics. It is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. RTW Investments' disclosure of a 9.3% stake in Tango Therapeutics, a biotechnology company, suggests a strategic investment in the sector.

Stakeholder Impact

• Shareholders: The disclosure may influence investor perception of Tango Therapeutics due to the significant stake held by an established investment firm.
• Management: The company's management will be aware of RTW Investments' substantial ownership and potential influence.

Next Steps

• RTW Investments and Roderick Wong will continue to hold or potentially adjust their stake in Tango Therapeutics.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership.

Key Dates

Keywords

Tango Therapeutics, Schedule 13G, RTW Investments, Roderick Wong, Beneficial Ownership, Investment Adviser, Common Stock, SEC Filing, Securities Exchange Act